Sarcosine
10 benefits mapped to clinical evidence across supplements.
Dose per serving from research
13 study groups in 11 studies say how much Sarcosine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 92% of 13 study groups.
| Daily dose | Study groups |
|---|---|
| 1 g or less | 1 |
| 1 g to 2.5 g | 12 |
Benefit Evidence
Brain markers + symptoms
Depression benefit +19%
Schizophrenia symptoms −19%
Sharper cognition/negative symptoms
~19-30% better
Global psychiatric gains
Research sources
Mood balance (11)
- Efficacy and safety of add-on sarcosine in patients with major depressive disorder: A randomized controlled trial
PubMed ID: 39180989
Randomized add‑on trial in depression showed significantly larger MADRS reductions and higher remission/response.
- Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia
PubMed ID: 26306650
Hippocampal biochemical and clinical improvements could translate to more social activity.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunctive reduction in negative symptoms (which impair social engagement) supports improved social functioning.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
SANS improvements likely translate to greater social interest/engagement.
- Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression
PubMed ID: 23562005
Small randomized double‑blind trial showed sarcosine produced larger and faster antidepressant effects vs citalopram.
- Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia
PubMed ID: 24612097
PD dementia study showed early improvements in depression and behavioral symptoms, improving emotional balance.
- Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
PubMed ID: 26506383
Marked negative symptom improvement (social withdrawal/amotivation) suggests greater social engagement.
- Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
PubMed ID: 26501260
Prefrontal neuronal improvements plus symptom gains likely boost social functioning.
- Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
PubMed ID: 29417623
Schizophrenia augmentation reduced negative and total PANSS scores (mood/affect components improved).
- Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)
PubMed ID: 30130712
Chronic schizophrenia trial improved negative and general psychopathology (affective benefit plausible).
- Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study)
PubMed ID: 33245168
Six‑month add‑on improved negative and overall symptoms, consistent with mood/affect gains.
Brain health (10)
- Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia
PubMed ID: 24612097
PD dementia trial: temporary improvements in depression/behavior without motor harm—suggests safe neuropsychiatric benefit.
- Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression
PubMed ID: 23562005
Sarcosine produced larger and faster antidepressant effects vs citalopram—supports affective/brain health benefits.
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
6‑week add‑on trial found improved PANSS, SANS and GAF with sarcosine—supports brain health and function.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Well‑conducted RCT showing consistent symptom and cognitive improvements with sarcosine adjunct—strong support.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Double‑blind RCT: sarcosine adjunct improved positive/negative/cognitive symptoms—direct clinical brain‑health signal.
- Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia
PubMed ID: 26306650
Hippocampal glutamatergic marker decreases with clinical improvement indicate neurochemical brain benefit.
- Maternal choline intake modulates maternal and fetal biomarkers of choline metabolism in humans
PubMed ID: 22418088
Maternal choline intake RCT produced dose‑related increases in circulating sarcosine/DMG—direct physiologic relevance.
- Efficacy and safety of add-on sarcosine in patients with major depressive disorder: A randomized controlled trial
PubMed ID: 39180989
BDNF increases and symptomatic improvement support neuroplasticity/brain‑health effects in depression.
- Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
PubMed ID: 26501260
Randomized increase in prefrontal NAA (neuronal viability marker) with concurrent symptom benefit.
- Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
PubMed ID: 26506383
Strong randomized evidence: large decreases in glutamatergic markers in frontal white matter plus symptom improvement.
Daily comfort (9)
- Efficacy and safety of add-on sarcosine in patients with major depressive disorder: A randomized controlled trial
PubMed ID: 39180989
Depression RCT improved remission/response rates, likely improving day‑to‑day functioning.
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
Trial reported improved Global Assessment of Functioning (GAF) with sarcosine—direct evidence for better daily functioning.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Significant clinical and negative‑symptom improvements in a well‑powered trial imply real functional gains.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunctive symptom improvements (multi‑domain) are consistent with better day‑to‑day functioning.
- Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
PubMed ID: 29417623
Negative and total PANSS reductions indicate improved daily functioning potential.
- Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
PubMed ID: 26501260
Symptomatic improvements plus neuronal marker increases imply better everyday function.
- Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
PubMed ID: 26506383
Large randomized trial reported substantial PANSS improvements consistent with functional gains.
- Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression
PubMed ID: 23562005
Antidepressant benefits and higher remission rates likely translate to improved daily functioning in depressed patients.
- Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)
PubMed ID: 30130712
Chronic schizophrenia improvement in negative/general psychopathology suggests functional benefit.
Motivation & confidence (8)
- Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
PubMed ID: 26506383
Substantial reductions in negative symptoms (amotivation component) in a randomized trial.
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
Global and negative‑symptom improvements imply likely gains in motivation for some patients.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Significant improvement in SANS (negative symptoms, including avolition) supports increased motivation.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunctive improvements included negative symptoms, consistent with improved motivational domains.
- Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study)
PubMed ID: 33245168
Consistent negative symptom improvement supports motivation gains.
- Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)
PubMed ID: 30130712
Chronic schizophrenia add‑on improved negative symptoms (motivation‑related).
- Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study)
PubMed ID: 29417623
Negative symptom improvements indicate likely increases in motivation.
- Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
PubMed ID: 26501260
NAA increases and PANSS improvement imply better drive/initiative.
Focus & concentration (4)
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunctive improvements in cognitive symptoms are compatible with better attention span.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Cognitive subscale gains consistent with improved sustained attention in acute schizophrenia patients.
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
Short add‑on trial showed cognitive and global improvements suggesting attention benefits.
- Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
PubMed ID: 26506383
Biochemical normalization in frontal regions and symptom gains support sharper cognition.
Mental clarity (4)
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunct sarcosine improved cognitive/general psychiatric symptoms—supports clearer thinking.
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
Add‑on trial showed improved global functioning and negative/cognitive symptoms.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Large adjunctive trial with clear cognitive/negative‑symptom improvement consistent with greater clarity.
- Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
PubMed ID: 26506383
Marked reductions in frontal glutamatergic markers and clinical improvement suggest clearer cognition.
Learning (3)
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
6‑week add‑on RCT showed cognitive and global gains, consistent with faster cognitive processing.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Adjunctive sarcosine improved cognitive subscores robustly—consistent with gains in processing speed.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunctive cognition/psychiatric improvements plausibly aid decision processes.
Memory (3)
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
PubMed ID: 19887019
Cognitive improvements in a short add‑on trial suggest possible gains in verbal recall.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Improvements in cognitive PANSS subscores are compatible with better verbal memory/recall.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Adjunctive improvements in cognitive/general psychiatric symptoms likely include verbal recall gains.
Stress resilience (2)
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
PubMed ID: 16275807
Clinical improvements across negative/cognitive domains can foster better functional resilience.
- Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression
PubMed ID: 23562005
Rapid antidepressant response and higher remission can reflect improved resilience to stressors.
Energy & Fatigue (2)
- Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression
PubMed ID: 23562005
Antidepressant trial reported faster symptomatic relief which often includes reduced fatigue and improved energy.
- Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia
PubMed ID: 24612097
PD dementia study noted improvements in neuropsychiatric symptoms early in treatment that may reduce mental fatigue.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Sarcosine
Search all4 products whose verified label declares Sarcosine — not every bottle that mentions it in a title.